Thomas Smith, vice president of medical affairs at Teva Neuroscience, said: “The thinner, 29-gauge needle further demonstrates Teva’s commitment to continued research and development of Copaxone to help provide treatment benefits over the long term.
“In addition to helping improve patients injection experiences by potentially lessening pain and reactions, the new needle may help to ensure adherence with treatment that has been shown to significantly improve patient outcomes.”